lomustine

This is the second study associating hypercalcaemia with improved PFS in dogs with non-indolent T-cell lymphoma. Results also suggest prognostic significance of specific CD4/CD8 expression patterns.

P1/2, N=18, Active, not recruiting, Azienda Ospedaliera Universitaria Meyer IRCCS | Not yet recruiting --> Active, not recruiting

As a result, three repurposed drugs were identified as priorities: (i) mefloquine (reference drug: vorasidenib citrate), (ii) clofibric acid (reference drug: carmustine), and armillarisin A (reference drug: lomustine). These results also suggest repurposing candidates for synergistic combinations across different brain tumors. The two applications developed in this work are freely accessible and in the public domain at https://assay.smallmoles.com/escorwin.

P3, N=225, Recruiting, Children's Oncology Group | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2029

P2/3, N=30, Not yet recruiting, Telix Pharmaceuticals (Innovations) Pty Limited

P3, N=265, Active, not recruiting, NRG Oncology | Suspended --> Active, not recruiting

P2, N=45, Active, not recruiting, Children's Oncology Group | Trial completion date: Jun 2027 --> Mar 2028 | Trial primary completion date: Jun 2027 --> Mar 2028

Here the authors report the effects of the off-label use of ivosidenib. The INDIGO trial published evidence of efficacy in using an IDH inhibitor for low-grade gliomas. The role of these drugs in high-grade IDH-mutant gliomas is currently unknown. Further studies are needed to assess their impact on overall and progression-free survival. https://thejns.org/doi/10.3171/CASE25572.

In this discourse, we delineate the case of a 42-year-old male patient diagnosed with IDH-wild-type, MGMT-unmethylated, TERT promoter-mutated, and EGFR-amplified GBM, who manifested an early recurrence during adjuvant temozolomide therapy. Our findings, contextualized within contemporary evidence on re-irradiation (stereotactic radiosurgery/fractionated stereotactic radiation therapy) and combinatorial strategies (BEV with lomustine or irinotecan), underscore the need for further empirical investigation to optimize treatment sequencing in r-GBM. This case emphasizes the necessity for individualized multimodal approaches to improve outcomes in this refractory patient population.

Here, we report atypical clinicopathological features observed in the case of CEL. These findings have potential biological, diagnostic, and prognostic relevance, emphasizing the need for further studies to elucidate their clinical significance and to expand the understanding of this disease.

P3, N=406, Recruiting, University Hospital Heidelberg | Trial completion date: Mar 2031 --> Mar 2033 | Trial primary completion date: Mar 2031 --> Mar 2033

P3, N=306, Suspended, NRG Oncology | Recruiting --> Suspended